ContraFect (CFRX) Releases Quarterly Earnings Results, Beats Estimates By $0.04 EPS

ContraFect (NASDAQ:CFRX) issued its quarterly earnings results on Thursday. The biotechnology company reported ($0.06) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.10) by $0.04, MarketWatch Earnings reports.

Shares of ContraFect stock traded down $0.19 on Friday, hitting $2.19. 153,143 shares of the company’s stock were exchanged, compared to its average volume of 172,183. The stock has a market capitalization of $175.49 million, a PE ratio of -5.92 and a beta of -0.37. ContraFect has a 1 year low of $0.85 and a 1 year high of $2.93.

Separately, ValuEngine upgraded shares of ContraFect from a “hold” rating to a “buy” rating in a research note on Tuesday.

WARNING: This story was originally reported by WKRB News and is owned by of WKRB News. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at https://www.wkrb13.com/2018/11/10/contrafect-cfrx-releases-quarterly-earnings-results-beats-estimates-by-0-04-eps.html.

About ContraFect

ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that is in Phase II human clinical trials for the treatment of Staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic varieties of human influenza.

Featured Story: Short Selling Stocks, A Beginner’s Guide

Earnings History for ContraFect (NASDAQ:CFRX)

Receive News & Ratings for ContraFect Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply